Disseminated intravascular coagulation in infectious disease

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 4, 2010, Pages 367-377

  Levi, Marcel ^a   Schultz, Marcus ^a   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

antithrombin; cytokines; Disseminated intravascular coagulation; fibrinolysis; infection; inflammation; protein C; tissue factor

Indexed keywords

ANTITHROMBIN; CYTOKINE; PROTEIN C; THROMBOPLASTIN;

BLOOD CLOTTING; CHIKUNGUNYA; DENGUE; DISSEMINATED INTRAVASCULAR CLOTTING; EBOLA HEMORRHAGIC FEVER; ENDOTHELIUM; FIBRINOLYSIS; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC FEVER; HEMOSTASIS; HUMAN; INFECTION; INFLAMMATION; MARBURG HEMORRHAGIC FEVER; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULITIS; YELLOW FEVER; ANIMAL; BACTERIAL INFECTION; BLOOD; MICROBIOLOGY; VIRUS INFECTION;

ANIMALS; BACTERIAL INFECTIONS; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; INFLAMMATION; VIRUS DISEASES;

EID: 77954403383     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1254046     Document Type: Review

References (111)

1. Levi M. Disseminated intravascular coagulation. Crit Care Med 2007 35 (9) 2191-2195
2. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999 341 (8) 586-592
3. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010 38 (2, suppl) S26-S34
4. Aird W C. Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis. Crit Care Med 2001 29 (7, suppl) S28-S34, discussion S34S35
5. Wheeler A P., Bernard G R. Treating patients with severe sepsis. N Engl J Med 1999 340 (3) 207-214
6. Levi M, de Jonge E, van der Poll T, ten Cate H. Disseminated intravascular coagulation. Thromb Haemost 1999 82 (2) 695-705
7. Anas A, Wiersinga W J., de Vos A F., van der Poll T. Recent insights into the pathogenesis of bacterial sepsis. Neth J Med 2010 68 147-152
8. ten Cate J W., van der Poll T, Levi M, ten Cate H, van Deventer S J. Cytokines: triggers of clinical thrombotic disease. Thromb Haemost 1997 78 (1) 415-419
9. Levi M, ten Cate H, van der Poll T. Endothelium: interface between coagulation and inflammation. Crit Care Med 2002 30 (5, suppl) S220-S224
10. Vallet B. Microthrombosis in sepsis. Minerva Anesthesiol 2001 67 (4) 298-301
11. Levi M, van der Poll T, ten Cate H, van Deventer S J. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest 1997 27 (1) 3-9
12. Ruf W, Edgington T S. Structural biology of tissue factor, the initiator of thrombogenesis in vivo. FASEB J 1994 8 (6) 385-390
13. Camerer E, Kolstø A B., Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996 81 (1) 1-41
14. Banner D W., D'Arcy A, Chène C et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. [see comments] Nature 1996 380 (6569) 41-46
15. ten Cate H, Bauer K A., Levi M et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993 92 (3) 1207-1212
16. Osterud B. Tissue factor expression by monocytes: regulation and pathophysiological roles. Blood Coagul Fibrinolysis 1998 9 (suppl 1) S9-S14
17. Giesen P L., Rauch U, Bohrmann B et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999 96 (5) 2311-2315
18. Nieuwland R, Berckmans R J., McGregor S et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000 95 (3) 930-935
19. Koyama T, Nishida K, Ohdama S et al. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 1994 87 (2) 343-347
20. Levi M, Schouten M, van der Poll T. Sepsis, coagulation, and antithrombin: old lessons and new insights. Semin Thromb Hemost 2008 34 (8) 742-746
21. Mann K G. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999 82 (2) 165-174
22. Mesters R M., Mannucci P M., Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. [see comments] Blood 1996 88 (3) 881-886
23. Jochum M, Lander S, Heimburger N, Fritz H. Effect of human granulocytic elastase on isolated human antithrombin III. Hoppe Seylers Z Physiol Chem 1981 362 (2) 103-112
24. Bourin M C., Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. Biochem J 1993 289 (Pt 2) 313-330
25. Kobayashi M, Shimada K, Ozawa T. Human recombinant interleukin-1 beta- and tumor necrosis factor alpha-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells. J Cell Physiol 1990 144 (3) 383-390
26. Kessler C M., Tang Z, Jacobs H M., Szymanski L M. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus -induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood 1997 89 (12) 4393-4401
27. Taylor F BJ Jr, Chang A C., Peer G T. et al. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 1991 78 (2) 364-368
28. Minnema M C., Chang A C., Jansen P M. et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000 95 (4) 1117-1123
29. Levi M. Activated protein C in sepsis: a critical review. Curr Opin Hematol 2008 15 (5) 481-486
30. Esmon C T. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989 264 (9) 4743-4746
31. Bouma B N., Meijers J C. Fibrinolysis and the contact system: a role for factor XI in the down-regulation of fibrinolysis. Thromb Haemost 1999 82 (2) 243-250
32. Esmon C T., Xu J, Gu J M. et al. Endothelial protein C receptor. Thromb Haemost 1999 82 (2) 251-258
33. Hancock W W., Tsuchida A, Hau H, Thomson N M., Salem H H. The anticoagulants protein C and protein S display potent antiinflammatory and immunosuppressive effects relevant to transplant biology and therapy. Transplant Proc 1992 24 (5) 2302-2303
34. Taylor F BJ Jr, Dahlback B, Chang A C. et al. Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli. Blood 1995 86 (7) 2642-2652
35. Taylor F BJ Jr, Stearns-Kurosawa D J., Kurosawa S et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000 95 (5) 1680-1686
36. Taylor F BJ Jr, Chang A, Esmon C T., D'Angelo A, Vigano-D'Angelo S, Blick K E. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987 79 (3) 918-925
37. Furlan M, Robles R, Galbusera M et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. [see comments] N Engl J Med 1998 339 (22) 1578-1584 (Pubitemid 28536132)
38. Randolph M M., White G L., Kosanke S D. et al. Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coli a comparative study of treated and untreated non-surviving baboons challenged with LD100 E. coli. Thromb Haemost 1998 79 (5) 1048-1053
39. de Jonge E, Dekkers P E., Creasey A A. et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000 95 (4) 1124-1129
40. Biemond B J., Friederich P W., Koschinsky M L. et al. Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Circulation 1997 96 (5) 1612-1615
41. Schleef R R., Bevilacqua M P., Sawdey M, Gimbrone M AJ Jr, Loskutoff D J. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 1988 263 (12) 5797-5803
42. Yamamoto K, Loskutoff D J. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest 1996 97 (11) 2440-2451 (Pubitemid 26187331)
43. Sawdey M S., Loskutoff D J. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991 88 (4) 1346-1353
44. ten Cate H. Pathophysiology of disseminated intravascular coagulation in sepsis. Crit Care Med 2000 28 (9, suppl) S9-S11
45. Hermans P W., Hibberd M L., Booy R et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999 354 (9178) 556-560
46. Westendorp R G., Hottenga J J., Slagboom P E. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999 354 (9178) 561-563
47. Mesters R M., Flrke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis. Thromb Haemost 1996 75 (6) 902-907
48. Altieri D C. Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa. J Biol Chem 1994 269 (5) 3139-3142
49. Degen J L. Hemostatic factors and inflammatory disease. Thromb Haemost 1999 82 (2) 858-864
50. Johnson K, Choi Y, DeGroot E, Samuels I, Creasey A, Aarden L. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J Immunol 1998 160 (10) 5130-5135
51. Kahn M L., Nakanishi-Matsui M, Shapiro M J., Ishihara H, Coughlin S R. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999 103 (6) 879-887
52. Cunningham M A., Romas P, Hutchinson P, Holdsworth S R., Tipping P G. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood 1999 94 (10) 3413-3420
53. de Jonge E, Friederich P W., Vlasuk G P. et al. Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects. Clin Diagn Lab Immunol 2003 10 (3) 495-497
54. Esmon C T. Does inflammation contribute to thrombotic events? Haemostasis 2000 30 (suppl 2) 34-40
55. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001 29 (7 suppl) S90-S94
56. Bernard G R., Vincent J L., Laterre P F. et al, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 344 (10) 699-709
57. Levi M, Keller T T., van Gorp E, ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res 2003 60 (1) 26-39
58. Baglin T. Disseminated intravascular coagulation: diagnosis and treatment. BMJ 1996 312 (7032) 683-687
59. Bhamarapravati N. Hemostatic defects in dengue hemorrhagic fever. Rev Infect Dis 1989 11 (suppl 4) S826-S829
60. Mohanty D, Ghosh K, Nandwani S K. et al. Fibrinolysis, inhibitors of blood coagulation, and monocyte derived coagulant activity in acute malaria. Am J Hematol 1997 54 (1) 23-29
61. Chuttani K, Tischler M D., Pandian N G., Lee R T., Mohanty P K. Diagnosis of cardiac tamponade after cardiac surgery: relative value of clinical, echocardiographic, and hemodynamic signs. Am Heart J 1994 127 (4 Pt 1) 913-918
62. Fera G, Semeraro N, De Mitrio V, Schiraldi O. Disseminated intravascular coagulation associated with disseminated cryptococcosis in a patient with acquired immunodeficiency syndrome. Infection 1993 21 (3) 171-173
63. Schrder S, Spyridopoulos I, Knig J, Jaschonek K G., Luft D, Seif F J. Thrombotic thrombocytopenic purpura (TTP) associated with a Borrelia burgdorferi infection. Am J Hematol 1995 50 (1) 72-73
64. Gärdlund B, The Heparin Prophylaxis Study Group. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet 1996 347 (9012) 1357-1361
65. Laing R B., Brettle R P., Leen C L. Venous thrombosis in HIV infection. [editorial] Int J STD AIDS 1996 7 (2) 82-85
66. Hayes E B., Gubler D J. Dengue and dengue hemorrhagic fever. Pediatr Infect Dis J 1992 11 (4) 311-317
67. Gear J S., Cassel G A., Gear A J. et al. Outbreak of Marburg virus disease in Johannesburg. Br Med J 1975 4 489-493
68. Limbos M A., Lieberman J M. Disseminated intravascular coagulation associated with rotavirus gastroenteritis: report of two cases. [see comments] Clin Infect Dis 1996 22 (5) 834-836
69. McKay D G., Margaretten W. Disseminated intravascular coagulation in virus diseases. Arch Intern Med 1967 120 (2) 129-152
70. Linder M, Mller-Berghaus G, Lasch H G., Gagel C. Virus infection and blood coagulation. Thromb Diath Haemorrh 1970 23 (1) 1-11
71. Clemens R, Pramoolsinsap C, Lorenz R, Pukrittayakamee S, Bock H L., White N J. Activation of the coagulation cascade in severe falciparum malaria through the intrinsic pathway. Br J Haematol 1994 87 (1) 100-105
72. Badesha P S., Saklayen M G. Hemolytic uremic syndrome as a presenting form of HIV infection. Nephron 1996 72 (3) 472-475
73. Laing R W., Teh C, Toh C H. Thrombotic thrombocytopenic purpura (TTP) complicating leptospirosis: a previously undescribed association. [letter]. J Clin Pathol 1990 43 (11) 961-962
74. Ackerman A B., Chongchitnant N, Sanchez J, Guo Y. Inflammatory Diseases. Histologic Diagnosis of Inflammatory Skin Diseases. Baltimore, MD Williams and Wilkins 1997 170-186
75. Golden M P., Hammer S M., Wanke C A., Albrecht M A. Cytomegalovirus vasculitis. Case reports and review of the literature. Medicine (Baltimore) 1994 73 (5) 246-255
76. Booss J, Dann P R., Winkler S R., Griffith B P., Kim J H. Mechanisms of injury to the central nervous system following experimental cytomegalovirus infection. Am J Otolaryngol 1990 11 (5) 313-317
77. Libman B S., Quismorio F PJ Jr, Stimmler M M. Polyarteritis nodosa-like vasculitis in human immunodeficiency virus infection. J Rheumatol 1995 22 (2) 351-355
78. Calabrese L H. Vasculitis and infection with the human immunodeficiency virus. [review]. [53 refs] Rheum Dis Clin North Am 1991 17 (1) 131-147
79. Carson C W., Conn D L., Czaja A J., Wright T L., Brecher M E. Frequency and significance of antibodies to hepatitis C virus in polyarteritis nodosa. J Rheumatol 1993 20 (2) 304-309
80. Leruez-Ville M, Laugé A, Morinet F, Guillevin L, Dény P. Polyarteritis nodosa and parvovirus B19. Lancet 1994 344 (8917) 263-264
81. Nikkari S, Mertsola J, Korvenranta H, Vainionpää R, Toivanen P. Wegener's granulomatosis and parvovirus B19 infection. [see comments] Arthritis Rheum 1994 37 (11) 1707-1708
82. Stemerman M B., Colton C, Morell E. Perturbations of the endothelium. Prog Hemost Thromb 1984 7 289-324
83. Kaiser L, Sparks H V. Jr. Endothelial cells. Not just a cellophane wrapper. Arch Intern Med 1987 147 (3) 569-573
84. Friedman H M. Infection of endothelial cells by common human viruses. [see comments] Rev Infect Dis 1989 11 (suppl 4) S700-S704
85. Wiley C A., Schrier R D., Nelson J A., Lampert P W., Oldstone M B. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A 1986 83 (18) 7089-7093
86. Butthep P, Bunyaratvej A, Bhamarapravati N. Dengue virus and endothelial cell: a related phenomenon to thrombocytopenia and granulocytopenia in dengue hemorrhagic fever. Southeast Asian J Trop Med Public Health 1993 24 (suppl 1) 246-249
87. van Dam-Mieras M C., Muller A D., van Hinsbergh V W., Mullers W J., Bomans P H., Bruggeman C A. The procoagulant response of cytomegalovirus infected endothelial cells. Thromb Haemost 1992 68 (3) 364-370
88. McEver R P. GMP-140: a receptor for neutrophils and monocytes on activated platelets and endothelium. J Cell Biochem 1991 45 (2) 156-161
89. Anderson R, Wang S, Osiowy C, Issekutz A C. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. J Virol 1997 71 (6) 4226-4232
90. Sugerman R W., Church J A., Goldsmith J C., Ens G E. Acquired protein S deficiency in children infected with human immunodeficiency virus. Pediatr Infect Dis J 1996 15 (2) 106-111
91. Stahl C P., Wideman C S., Spira T J., Haff E C., Hixon G J., Evatt B L. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood 1993 81 (7) 1801-1807
92. Hassell K L., Kressin D C., Neumann A, Ellison R, Marlar R A. Correlation of antiphospholipid antibodies and protein S deficiency with thrombosis in HIV-infected men. Blood Coagul Fibrinolysis 1994 5 (4) 455-462
93. van Gorp E C., Minnema M C., Suharti C et al. Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever. Br J Haematol 2001 113 (1) 94-99
94. Levin J. Bleeding with infectious disease In: Ratnoff OD, Forbes CD Disorders of Hemostasis. Orlando, FL Grune and Stratton 1984 367-378
95. Nakao S, Lai C J., Young N S. Dengue virus, a flavivirus, propagates in human bone marrow progenitors and hematopoietic cell lines. [see comments] Blood 1989 74 (4) 1235-1240
96. Halstead S B. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis 1989 11 (suppl 4) S830-839
97. Myllylä G, Vaheri A, Vesikari T, Penttinen K. Interaction between human blood platelets, viruses and antibodies. IV. Post-rubella thrombocytopenic purpura and platelet aggregation by rubella antigen-antibody interaction. Clin Exp Immunol 1969 4 (3) 323-332
98. Charkes N D. Purpuric chickenpox: report of a case, review of the literature, and classification by clinical features. Ann Intern Med 1961 54 745-759
99. Chanarin I, Walford D M. Thrombocytopenic purpura in cytomegalovirus mononucleosis. Lancet 1973 2 (7823) 238-239
100. Levi M, Toh C H., Thachil J, Watson H G., British Committee for Standards in Haematology. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol 2009 145 (1) 24-33
101. Schultz M J. Early recognition of critically ill patients. Neth J Med 2009 67 (9) 266-267
102. Tromp M, Bleeker-Rovers C P., van Achterberg T et al. Internal medicine residents' knowledge about sepsis: effects of a teaching intervention. Neth J Med 2009 67 (9) 312-315
103. Warren B L., Eid A, Singer P et al, KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001 286 (15) 1869-1878
104. Kienast J, Juers M, Wiedermann C J. et al, KyberSept investigators. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006 4 (1) 90-97
105. Vincent J L., Angus D C., Artigas A et al, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003 31 (3) 834-840
106. Dhainaut J F., Yan S B., Joyce D E. et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004 2 (11) 1924-1933
107. Abraham E, Laterre P F., Garg R et al, Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005 353 (13) 1332-1341
108. Dellinger R P., Levy M M., Carlet J M. et al, International Surviving Sepsis Campaign Guidelines Committee American Association of Critical-Care Nurses American College of Chest Physicians American College of Emergency Physicians Canadian Critical Care Society European Society of Clinical Microbiology and Infectious Diseases European Society of Intensive Care Medicine European Respiratory Society International Sepsis Forum Japanese Association for Acute Medicine Japanese Society of Intensive Care Medicine Society of Critical Care Medicine Society of Hospital Medicine Surgical Infection Society World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008 36 (1) 296-327
109. Wiedermann C J., Kaneider N C. A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis. BMC Emerg Med 2005 5 7
110. Martí-Carvajal A, Salanti G, Cardona A F. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2007 (3) CD004388
111. Barie P S. All in for a huge pot: the PROWESS-SHOCK trial for refractory septic shock. Surg Infect (Larchmt) 2007 8 (5) 491-494